Skip to main content
HK

Hann-Chorng Kuo

Biography​

Hann-Chorng Kuo directs the Department of Urology at Hualien Tzu Chi Hospital, serves as vice chief executive officer of the Buddhist Tzu Chi Medical Foundation, and is a professor of urology at Tzu Chi University College of Medicine.1 Kuo graduated from National Taiwan University College of Medicine and trained in urology at National Taiwan University Hospital.1 Kuo is editor in chief of the Tzu Chi Medical Journal and previously served as president of the Taiwan Continence Society and the Taiwan Urological Association.12

Contributions​

Kuo's cited papers examine botulinum toxin delivery for overactive bladder, interstitial cystitis or bladder pain syndrome, and urethral sphincter dysfunction. Other cited work addresses urodynamic assessment and treatment of dysfunctional voiding.34567

Cited on WARWIKI

25 publications with Hann-Chorng Kuo as a listed author are cited on WARWIKI, ordered by the number of pages that cite them. Papers whose author list is shortened to "et al." before this name are not included.

  1. Jiang YH, Kuo HC. Current optimal pharmacologic therapies for overactive bladder. Expert Opin Pharmacother. 2023;24(18):2005–2019. doi
    Cited on: Anticholinergic / Antimuscarinic Agents · β3-Adrenergic Receptor Agonists
  2. Lee CL, Kuo HC. "Video urodynamic predictors of outcomes after urethral sphincter botulinum toxin A injection in spinal cord-injured patients with detrusor sphincter dyssynergia." Toxins. 2025;17(8):412. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  3. Chiang CH, Kuo HC. "The efficacy and mid-term durability of urethral sphincter injections of platelet-rich plasma in treatment of female stress urinary incontinence." Front Pharmacol. 2022;13:847520. doi
    Cited on: Platelet-Rich Plasma (PRP)
  4. Hung FC, Kuo HC. "Liposome-encapsulated botulinum toxin A in treatment of functional bladder disorders." Toxins. 2022;14(12):838. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  5. Kuo HC. "Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do?" Toxins. 2022;14(7):498. doi
    Cited on: Intradetrusor OnabotulinumtoxinA
  6. Chiang CH, Jiang YH, Kuo HC. "Therapeutic efficacy of biofeedback pelvic floor muscle exercise in women with dysfunctional voiding." Scientific Reports. 2021;11:13757. doi
    Cited on: Dysfunctional Voiding
  7. Jhang JF, Kuo HC. "Novel applications of non-invasive intravesical botulinum toxin A delivery in the treatment of functional bladder disorders." Toxins. 2021;13(5):359. doi
    Cited on: Botulinum Toxin (Neuromodulation Adjunct)
  8. Lee PJ, Jiang YH, Kuo HC. "A novel management for post-prostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection." Sci Rep. 2021;11(1):5371. doi
    Cited on: Platelet-Rich Plasma (PRP)
  9. Chuang YC, Meng E, Chancellor M, Kuo HC. "Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome — a prospective, multicenter, randomized, double-blind, placebo-controlled study." Neurourol Urodyn. 2020;39(5):1505–1514. doi
    Cited on: Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)
  10. Jhang JF, Kuo HC. "Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction." Toxins. 2018;10(7):E260. doi
    Cited on: Intradetrusor OnabotulinumtoxinA
  11. Jiang YH, Chen SF, Jhang JF, Kuo HC. "Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity." Neurourology and Urodynamics. 2018;37(8):2651-2657. doi
    Cited on: Dysfunctional Voiding
  12. Peng CH, Chen SF, Kuo HC. "Videourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction." Neurourology and Urodynamics. 2017;36(8):2169-2175. doi
    Cited on: Dysfunctional Voiding

Footnotes​

  1. 排尿障礙治療中心－郭漢崇. Accessed October 2026. ↩ ↩2 ↩3

  2. Hann-Chorng Kuo. UAA Congress 2025. Accessed October 2026. ↩

  3. Jiang YH, Liao CH, Kuo HC. "Current and potential urological applications of botulinum toxin A." Nat Rev Urol. 2015;12(9):519–533. doi:10.1038/nrurol.2015.193 ↩

  4. Hsiao SM, Lin HH, Kuo HC. "Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome." PLoS One. 2016;11(1):e0147137. doi:10.1371/journal.pone.0147137 ↩

  5. Lee CL, Kuo HC. "Video urodynamic predictors of outcomes after urethral sphincter botulinum toxin A injection in spinal cord-injured patients with detrusor sphincter dyssynergia." Toxins. 2025;17(8):412. doi:10.3390/toxins17080412 ↩

  6. Hung FC, Kuo HC. "Liposome-encapsulated botulinum toxin A in treatment of functional bladder disorders." Toxins. 2022;14(12):838. doi:10.3390/toxins14120838 ↩

  7. Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC. "Bladder instillation of liposome-encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial." J Urol. 2014;192(6):1743–1749. doi:10.1016/j.juro.2014.07.008 ↩